SynBiotic (DB:SBX) - Stock Price, News & Analysis

SBX Stock Overview

Engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. More details

SBX fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Trading at 88.5% below our estimate of its fair value

Earnings are forecast to grow 106.98% per year

Risk Analysis

Volatile share price over the past 3 months compared to the German market

Does not have a meaningful market cap (€28M)

Shareholders have been diluted in the past year

Does not have meaningful revenue (€4M)

SynBiotic SE Competitors

Biofrontera

XTRA:B8FK

€16.4m

Cantourage Group

XTRA:HIGH

€57.6m

Apontis Pharma

XTRA:APPH

€80.3m

Redx Pharma

DB:0RX

€65.0m

Price History & Performance

Summary of all time highs, changes and price drops for SynBiotic
Historical stock prices
Current Share Price	€5.32
52 Week High	€19.30
52 Week Low	€2.88
Beta	4.49
11 Month Change	-18.40%
3 Month Change	-13.36%
1 Year Change	70.51%
33 Year Change	-87.39%
5 Year Change	n/a
Change since IPO	-80.86%

Recent updates

Shareholder Returns

	SBX	DE Pharmaceuticals	DE Market
7D	-3.6%	-1.0%	0.2%
1Y	70.5%	-19.3%	8.5%

Return vs Industry: SBX exceeded the German Pharmaceuticals industry which returned -19.3% over the past year.

Return vs Market: SBX exceeded the German Market which returned 8.5% over the past year.

Price Volatility

Is SBX's price volatile compared to industry and market?
SBX volatility
SBX Average Weekly Movement	8.7%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

Stable Share Price: SBX's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: SBX's weekly volatility has decreased from 17% to 9% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2015	55	Lars Muller	www.synbiotic.com

SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. The company was formerly known as Ledgertech SE and changed its name to SynBiotic SE.

SynBiotic SE Fundamentals Summary

How do SynBiotic's earnings and revenue compare to its market cap?
SBX fundamental statistics
Market cap	€27.93m
Earnings (TTM)	-€10.63m
Revenue (TTM)	€3.86m

7.2x

P/S Ratio

-2.6x

P/E Ratio

Is SBX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SBX income statement (TTM)
Revenue	€3.86m
Cost of Revenue	€2.35m
Gross Profit	€1.51m
Other Expenses	€12.14m
Earnings	-€10.63m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-2.12
Gross Margin	39.01%
Net Profit Margin	-275.31%
Debt/Equity Ratio	23.7%

How did SBX perform over the long term?

See historical performance and comparison